Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Cediranib is being tested to assess its effectiveness on the growth of kidney cancer tumours and also how well it is tolerated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Cediranib

Criteria

Inclusion Criteria:

• Confirmation of metastatic or recurrent renal cell carcinoma

Exclusion Criteria:

• Certain types of previous anti-cancer therapy for Renal Cell Carcinoma

• Patients with type I insulin-dependent diabetes or poorly-controlled type II insulin-independent diabetes

• Patients with a history of poorly controlled high blood pressure